Alexander O. Schuth sold $465k of DNLI
COFO and Secretary at Denali Therapeutics Inc.. 15,558 shares at an average of $29.91, traded Nov 7, 2024, filed Nov 12, 2024.
Score components
- +15RoleOfficer
- +17Trade size$465k at market
- 0Share of holdings soldSold 8.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -21.5%, 3m -31.1%, 6m -52.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001714899-24-000218, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2024 | MOption exercise Common Stock10b5-1 | +15,558 | $5.28 | $82k | 193,624 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -12,333 | $29.68 | $366k | 181,291 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -2,925 | $30.72 | $90k | 178,366 | Nov 12, 2024 |
| Nov 7, 2024 | SOpen-market sale Common Stock10b5-1 | -300 | $31.29 | $9,387 | 178,066 | Nov 12, 2024 |
| Nov 7, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,558 | $0.00 | $0 | 53,379 | Nov 12, 2024 |
Related signals
Other insiders at Denali Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Denali Therapeutics Inc. | Peter Scott Chin Chief Medical Officer | $37k 1,654 shares | -1% | |
| 33Weak | Denali Therapeutics Inc. | Nancy Thornberry director | $262k 11,439 shares | -37% | |
| 18Weak | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $65k 2,768 shares | -1% | |
| 43Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $69k 3,339 shares | -11% | |
| 67Notable | Denali Therapeutics Inc. | Ryan J. Watts President and CEO | $751k 36,916 shares | -13% | |
| 44Moderate | Denali Therapeutics Inc. | Alexander O. Schuth COFO and Secretary | $308k 15,162 shares | -6% | |
| 44Moderate | Denali Therapeutics Inc. | Carole Ho Chief Medical Officer | $308k 15,162 shares | -8% | |
| 18Weak | Denali Therapeutics Inc. | Vicki L Sato director | $64k 3,080 shares | -3% | |
| 50Moderate | Denali Therapeutics Inc. | Steve E. Krognes director | $608k 30,000 shares | -51% | |
| 40Moderate | Denali Therapeutics Inc. | David P Schenkein director | $1.9M 59,441 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.